Clinical Study

A Phase 2, Randomized, Placebo-Controlled Study To Evaluate Safety, Tolerability, And Efficacy Of Tak-079 In Patients With Generalized Myasthenia Gravis

Posted Date: Mar 5, 2021

  • Investigator: Hani Kushlaf
  • Specialties:
  • Type of Study: Drug

This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of TAK-079 in patients with generalized myasthenia gravis (MG) in combination with standard background therapy.

Criteria:

Generalized Mg Positive Anti–Acetylcholine Receptor (Achr) Or Anti–Muscle-Specific Tyrosinekinase (Musk) Antibodies, Class Ii To Iv Disease According To The Myasthenia Gravis Foundation Of America (Mgfa), And A Myasthenia Gravis-Activities Of Daily Living (Mg-Adl) Score Of 6 Or Higher.

Keywords:

Mg

For More Information:

Elizabeth Gehlmann
513-558-4497
gehlmaem@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.